| Abstract | Cilj istraživanja: U ovom istraživanju određene su demografske i patohistološke karakteristike infiltrativnog urotelnog karcinoma mokraćnog mjehura u bolesnika čiji su uzorci obrađeni na Kliničkom zavodu za patologiju, sudsku medicinu i citologiju KBC-a Split tijekom 2019. godine i 2020., godine koju je obilježila pandemija SARS-CoV-2. Uspoređen je broj, spol i dob bolesnika, a potom su analizirane i uspoređene patohistološke karakteristike - dubina invazije i histološki gradus tumora te vrsta uzorka.
Ispitanici i metode: Iz baze podataka Kliničkoga zavoda za patologiju, sudsku medicinu i citologiju KBC-a Split izdvojeni su patohistološki nalazi bolesnika s MKB šifrom C67 u razdoblju od 1. siječnja 2019. do 31. prosinca 2020. godine. Obrađeni su patohistološki nalazi svih bolesnika kojima je novodijagnosticiran infiltrativni urotelni karcinom mokraćnog mjehura.
Rezultati: U dvije promatrane godine utvrđene su statistički značajne razlike u broju oboljelih od infiltrativnog urotelnog karcinoma (P=0,022). Nije promijenjena dobna struktura bolesnika (P=0,948), ali je utvrđeno statistički značajno manje oboljelih muškaraca u 2020. godini pandemije SARS-CoV-2 (P=0,011), dok ta razlika nije utvrđena u žena (P=0,793). Broj bolesnika kojima je karcinom otkriven s visokim gradusom u 2020. godini statistički nije značajno smanjen u odnosu na 2019. godinu (P=0,101), kao ni broj bolesnika kojima je karcinom otkriven s niskim histološkim gradusom (P=0,197). Razlika među bolesnicima s karcinomom stadija T1 nije statistički značajna kad se uspoređuje 2019. godina s 2020. godinom (P=0,647), kao ni razlika broja bolesnika stadija T3 (P=1) i stadija T4 (P=0,317). Međutim, uočeno je statistički značajno smanjenje broja bolesnika s karcinomom stadija T2 (P=0,0004) u 2020. godini.
Zaključci: U 2020. godini pandemije SARS-CoV-2 dijagnosticirano je statistički značajno manje novootkrivenih infiltrativnih urotelnih karcinoma mokraćnog mjehura u usporedbi s 2019. godinom. Broj muškaraca kojima je dijagnosticiran infiltrativni urotelni karcinom u 2020. godini je bio značajno manji u odnosu na 2019. godinu, za razliku od žena u kojih ta razlika nije utvrđena. Dobna struktura nije bila statistički značajno promijenjena. Najveći udio uzoraka za patohistološku analizu dobiven je TUR-om, pa zatim radikalnim zahvatom u obje analizirane godine. Histološki gradus infiltrativnog urotelnog karcinoma nije bio statistički značajno promijenjen dok je dubina invazije bila statistički značajno promijenjena samo u bolesnika s mišićno- invazivnim urotelnim karcinomom (pT2) kojih je dijagnosticirano manje u 2020. godini pandemije SARS-CoV-2 u usporedbi s bolesnicima iz 2019. godine. |
| Abstract (english) | Objectives: This study determined the demographic and pathohistological characteristics of infiltrative urothelial bladder cancer in patients whose samples were processed at the Department of Pathology during 2019 and 2020, the year marked by the SARS-CoV-2 pandemic.
Materials and methods: The pathohistological findings of a patient with ICD code C67 in the period from 1 January 2019 to 31 December 2020 were extracted from the database of the Department of Pathology. Pathohistological findings of all patients newly diagnosed with infiltrative urothelial bladder cancer were processed.
Results: In the two observed years, statistically significant differences were found in the number of patients with infiltrative urothelial cancer (P=0.022). The age structure of patients was not changed (P=0.948), but statistically significantly reduced were newly diagnosed infiltrative urothelial cancer in man in the 2020, year marked by the SARS-CoV-2 pandemic (P=0.011), while this difference was not found in women (P=0.793). The number of patients diagnosed with high-grade cancer in 2020 was not statistically significantly reduced compared to 2019 (P=0.101), nor was the number of patients diagnosed with low-grade cancer histological grade (P=0.197). The difference between patients with stage T1 cancer is not statistically significant when comparing 2019 with 2020 (P=0.647), nor the difference in the number of patients with stage T3 (P=1) and stage T4 (P=0.317). However, a statistically significant decrease in the number of patients with stage T2 cancer was observed (P=0.0004) in 2020.
Conclusions: In 2020, the SARS-CoV-2 pandemic was diagnosed with statistically significantly fewer newly diagnosed infiltrative urothelial bladder cancers compared to 2019. The number of men diagnosed with infiltrative urothelial cancer in 2020 was significantly lower than in 2019. The age structure was not statistically significantly changed. The largest share of samples for pathohistological analysis was obtained by TUR, followed by radical intervention in both analyzed years. The histological grade of infiltrative urothelial carcinoma was not statistically significantly changed while the depth of invasions was statistically significantly changed only in patients with muscular-invasive urothelial carcinoma (pT2) who were diagnosed less in the 2020 compared to 2019 |
